Table 4.
Major trials in HCC involving anti-PD1 agents-based immunotherapies.
| Name | Phase | Line of Treatment | Strategy | Primary Endpoint |
|---|---|---|---|---|
| NCT03864211 | 1/3 | II | Toriplimab (anti-PD-1) | AEs (Adverse Events) ORR (Overall Response Rate) |
| NCT03914352 | SHR-1210 (anti-PD-1) | OS (Overall Survival) DFS (Disease-Free Survival) |
||
| NCT03605706 | 3 | I | SHR-1210 + FOLFOX4 FOLFOX4 Sorafenib (Raf inhibitor) |
OS |
| NCT04191889 | 2 | FOLFOX + Apatinib (VEGFR-2 inhibitor) + Camrelizumab (SHR-1210) | ORR | |
| NCT04152356 | I | PD-1 + Sorafenib | DFS | |
| NCT04220944 | 1 | I | Sintilimab (anti-PD-1) | PFS (Progression Free Survival) |
| NCT04174781 | 2 | Sintilimab | PFS | |
| NCT04167293 | 2/3 | I | Sintilimab | 24-week PFS |
| NCT04229355 | 3 | I | Lenvatinib (VEGFRs inhibotor)vs. PD-1 inhibitor | PFS |
| NCT03949231 | 3 | Toripalimab | OS | |
| NCT03966209 | 1 | II | JS001 (PD-1 inhibitor) | Adverse Events Rate Graft Rejection Rate |
| NCT03655613 | 1/2 | II | APL-501 (PD-1 inhibitor) + APL-101 (c-Met inhibitor) | DLT (Dose Limiting Toxicity) |
| NCT04172506 | 1/2 | II | AK105 (anti PD-1) | ORR |
| NCT03680508 | 2 | I | TSR-022 (anti-TIM-3) + TSR-042 (anti-PD-1) | OR (Objective Response) |
| NCT03939975 | 2 | II | Pembrolizumab (anti-PD-1/PD-L1) Nivolumab (anti-PD-1/PD-L1) JS001 |
AEs Response |
| NCT02988440 | 1 | PDR001 (anti-PD-1)+ Sorafenib | AEs | |
| NCT02795429 | 2 | II | PDR001 +/− INC280 (c-Met/HGFR inhibitor) | DLT ORR |
| NCT03474640 | 1 | II | Toripalimab | AEs |